Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000104.xml
Zentralbl Chir 2023; 148(05): 389-391
DOI: 10.1055/a-2148-1979
DOI: 10.1055/a-2148-1979
Aktuelle Chirurgie
Stellenwert der Checkpoint Therapie bei viszeral-onkologischen Erkrankungen
Die Checkpoint-Inhibition hat sich als weitere Säule der onkologischen Therapie etabliert und ist auch bei Tumoren des Gastrointestinaltraktes von zunehmender Bedeutung. Dieser Artikel fasst den aktuellen Stand der Zulassung der Immun-Checkpoint-Inhibition bei viszeralonkologischen Erkrankungen zusammen.
Publication History
Article published online:
16 October 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Kaufmann SHE. Immunology’s foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nat Immunol 2008; 9: 705-712 DOI: 10.1038/ni0708-705. (PMID: 18563076)
- 2 Blank CU, Haanen JB, Ribas A. et al. The “cancer immunogram”. Science 2016; 352: 658-660 DOI: 10.1126/science.aaf2834. (PMID: 27151852)
- 3 Litchfield K, Reading JL, Puttick C. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 2021; 184: 596-614.e14 DOI: 10.1016/j.cell.2021.01.002. (PMID: 33508232)
- 4 Callahan MK, Postow MA, Wolchok JD. Targeting T Cell Co-receptors for Cancer Therapy. Immunity 2016; 44: 1069-1078 DOI: 10.1016/j.immuni.2016.04.023. (PMID: 27192570)
- 5 Sun JM, Shen L, Shah MA. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021; 398: 759-771 DOI: 10.1016/S0140-6736(21)01234-4. (PMID: 34454674)
- 6 Janjigian YY, Shitara K, Moehler M. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398: 27-40 DOI: 10.1016/S0140-6736(21)00797-2. (PMID: 34102137)
- 7 Kelly RJ, Ajani JA, Kuzdzal J. et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 2021; 384: 1191-1203 DOI: 10.1056/nejmoa2032125. (PMID: 33789008)
- 8 Chalabi M, Fanchi LF, Dijkstra KK. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020; 26: 566-576 DOI: 10.1038/s41591-020-0805-8. (PMID: 32251400)
- 9 Cercek A, Lumish M, Sinopoli J. et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022; 386: 2363-2376 DOI: 10.1056/NEJMOA2201445. (PMID: 35660797)
- 10 Finn RS, Qin S, Ikeda M. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894-1905 DOI: 10.1056/NEJMoa1915745. (PMID: 32402160)
- 11 Oh D-Y, He AR, Qin S. et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid 2022; DOI: 10.1056/EVIDoa2200015.
- 12 Johnson BA, Yarchoan M, Lee V. et al. Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin Cancer Res 2017; 23: 1656-1669 DOI: 10.1158/1078-0432.CCR-16-2318. (PMID: 28373364)